Guenter Janhofer - Oct 23, 2023 Form 4 Insider Report for Quince Therapeutics, Inc. (QNCX)

Role: Chief Scientific Officer
Signature: /s/ Brendan Hannah, Attorney-in-Fact for Guenter Janhofer, M.D., Ph.D.
Stock symbol: QNCX
Transactions as of: Oct 23, 2023
Transactions value $: $0
Form type: 4
Date filed: 10/24/2023, 07:42 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	QNCX	Employee Stock Option (right to buy)	Award	$0	+300K		$0.00	300K	Oct 23, 2023	Common Stock	300K	$0.99	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Twenty-five percent of the shares subject to the stock option vests on the first anniversary of the grant date of October 23, 2023, and the remainder vests in 36 equal monthly installments thereafter for the following three years, subject to the Reporting Person's continuous service as the officer of the Issuer as of each such date.